Asia FX cautious amid US govt shutdown; yen tumbles after Takaichi’s LDP win
Investing.com - H.C. Wainwright has assumed coverage on Inventiva SA (NASDAQ:IVA) with a Buy rating and a price target of $20.00, according to a research note released Wednesday. The company, currently valued at approximately $758 million, has seen its stock surge over 145% year-to-date, according to InvestingPro data.
The firm cited the FDA’s recent acceptance of a letter of intent for liver stiffness measurement as a surrogate endpoint, which H.C. Wainwright believes comes at an opportune time for Inventiva’s drug development efforts.
The regulatory decision helps qualify VCTE liver stiffness as a reasonably likely surrogate endpoint for MASH (Metabolic dysfunction-Associated SteatoHepatitis) outcomes and adds positive momentum for the company’s NATiV3 clinical program for its drug candidate lanifibranor.
H.C. Wainwright noted that recent key opinion leader discussions support lanifibranor’s differentiated therapeutic profile, highlighting its dual histologic and metabolic benefits, particularly in Type 2 diabetes plus MASH patients, along with oral dosing convenience and combination potential with other medications.
The price target represents an increase from a previous target of $13, with the firm explaining it has re-evaluated its penetration assumptions and probability of success based on the FDA’s encouraging stance on surrogate biomarkers.
In other recent news, Inventiva has seen notable developments, particularly in the context of its financial prospects and executive appointments. Guggenheim raised its price target for Inventiva to $13 from $9, maintaining a Buy rating, reflecting increased optimism around the market potential for the company’s lanifibranor treatment. Piper Sandler also initiated coverage with an Overweight rating and set a $26 price target, citing the potential of lanifibranor as a treatment for metabolic dysfunction-associated steatohepatitis (MASH), with key Phase 3 results expected in the second half of 2026.
In executive news, Inventiva appointed Jason Campagna as President of Research and Development and Chief Medical Officer, and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance. Campagna’s previous roles include Chief Medical Officer at Q32 Bio and MASH Global Program Lead at Intercept Pharmaceuticals. Additionally, Renée Aguiar-Lucander, former CEO of Calliditas, has joined Inventiva’s Board of Directors following approval at the company’s Annual General Meeting. These appointments are part of Inventiva’s ongoing efforts to advance its lead drug candidate, lanifibranor, through late-stage clinical development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.